Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment
This study will use real-world data to assess prevalence of brain metastases in metastatic non-small cell lung cancer (mNSCLC) patients and its impact on associated clinical outcomes.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Dec 9, 2024 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Daiichi Sankyo
- Interventions being studied
- Other: No drug
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
1. Diagnosis of mNSCLC in study period (01/01/2015-06/30/2023) including newly diagnosed at metastatic stage or progression from advanced stage NSCLC 2. Age 18+ years at the time of diagnosis of mNSCLC Additional inclusion criteria for 1st Line of Therapy cohort: 3. Treated with systemic anti-cancer therapy in 1L setting Additional inclusion criteria for 2nd Line of Therapy and 3rd Line of Therapy cohorts: 4. Treated with systemic anti-cancer therapy in 2L setting treated with systemic anti-cancer therapy in 3L setting
1. Evidence of other primary malignancy in the 365-day baseline period immediately prior to the first mNSCLC diagnosis in the study period 2. Evidence of stereotactic radiosurgery (SRS), stereotactic radiation therapy (SRT), or whole brain radiotherapy (WBRT) in the baseline period
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- ConcertAI DatabaseCambridge, Massachusetts
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 9, 2024. Always confirm current availability with the study team.